United Kingdom: Food, Drugs, Healthcare, Life Sciences

An investigation is underway after multiple sclerosis patients in the UK reported adverse effects following a switch from the originator medicine Tysabri to its biosimilar Tyruko. Despite regulatory approval confirming no clinically meaningful differences between the two natalizumab-based treatments, subtle variations in manufacturing processes, formulation buffers, and molecular characteristics may explain why some patients have experienced worsening symptoms or side effects.

Investigations into NHS paediatric audiology services have revealed systemic failures affecting hundreds of children, including delayed assessments and missed hearing loss diagnoses that may have impacted speech, language and educational development. Families affected by these failures in care may have legal options to pursue compensation where delays caused avoidable harm and lost opportunities for early intervention. Understanding the scope of these failures and the potential consequences for children's d

As artificial intelligence transforms healthcare and life sciences, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) is shaping a new regulatory framework through its Call for Evidence and AI sandbox initiatives. These developments signal a shift toward lifecycle-based oversight, continuous monitoring, and principles-based regulation that balances innovation with patient safety and accountability.